deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT03556345

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2

A Multicenter, Open Label，Single Arm，Phase II Study to Evaluate the Effect and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection in HER2 Overexpressing Local Advanced or Metastatic Gastric Cancer

Sponsor: RemeGen Co., Ltd.

Conditions Gastric Cancer HER2 Overexpressing Gastric Carcinoma
Interventions RC48-ADC
Updated 11 times since 2018 Last updated: Jan 12, 2022 Started: Jul 10, 2018 Primary completion: Jun 1, 2020 Completion: Aug 31, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Gastric Cancer and HER2 Overexpressing Gastric Carcinoma, this trial is completed. The trial is conducted by RemeGen Co., Ltd. and has accumulated 11 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jul 2018 – ~Jun 2019 · 11 months · monthly snapshotRecruiting~Jun 2019 – ~Aug 2019 · 2 months · monthly snapshotRecruiting~Aug 2019 – ~Mar 2020 · 7 months · monthly snapshotRecruiting~Mar 2020 – ~Jul 2020 · 4 months · monthly snapshotRecruiting~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshotActive Not Recruiting~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshotActive Not Recruiting~Oct 2021 – ~Feb 2022 · 4 months · monthly snapshotActive Not Recruiting~Feb 2022 – ~Jul 2024 · 29 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 19 months · monthly snapshotCompleted~Jan 2026 – present · 3 months · monthly snapshotCompleted

Change History

11 versions recorded

  1. Jan 2026 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Present [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Feb 2022 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  5. Oct 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE2

▶ Show 6 earlier versions

  1. Jan 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE2

  2. Jul 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Mar 2020 — Jul 2020 [monthly]

    Recruiting PHASE2

  4. Aug 2019 — Mar 2020 [monthly]

    Recruiting PHASE2

  5. Jun 2019 — Aug 2019 [monthly]

    Recruiting PHASE2

  6. Jul 2018 — Jun 2019 [monthly]

    Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • RemeGen Co., Ltd.
Data source: RemeGen Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations